Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
A registration statement on Form S-3 (File No. 333-216573) relating to these securities has been previously filed with the
A copy of the final prospectus supplement relating to the offering has been filed with the
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the estimated net proceeds from the public offering; future expectations, plans and prospects for
View original content with multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-of-common-stock-300572150.html
SOURCE
Media and Investor Relations Contacts, Kristin Hodous, 617 714 6674, khodous@blueprintmedicines.com; Jim Baker, 617 844 8236, jbaker@blueprintmedicines.com